What is Otonomy?
Otonomy is a specialized biopharmaceutical enterprise focused on the development of transformative therapeutics for neurotology. The company distinguishes itself through the pioneering application of advanced drug delivery technology designed for the ear. By enabling sustained drug exposure from a single local administration, Otonomy addresses significant limitations in traditional treatment modalities. Its robust patent estate supports a diverse pipeline of products aimed at improving patient outcomes in hearing-related disorders. The company operates at the intersection of biotechnology and specialized medical device application, maintaining a market position that emphasizes both scientific rigor and clinical utility.
How much funding has Otonomy raised?
Otonomy has raised a total of $448.4M across 7 funding rounds:
Series A
$10M
Series B
$38.5M
Series C
$45.9M
Series D
$49M
Stock Offering
$104M
Stock Offering
$86M
Stock Offering
$115M
Series A (2010): $10M with participation from Avalon Ventures
Series B (2010): $38.5M led by RiverVest Venture Partners, Avalon Ventures, Novo Ventures, Domain Associates, and TPG Biotech
Series C (2013): $45.9M supported by RiverVest Venture Partners, Avalon Ventures, Osage University Partners, Novo Ventures, APERTURE Venture Partners, Domain Associates, OrbiMed, and TPG Biotech
Series D (2014): $49M featuring Novo Ventures, Domain Associates, OrbiMed, Federated Kaufmann Funds, TPG Biotech, Clough Capital Partners, Avalon Ventures, Ally Bridge Group, Osage University Partners, RiverVest Venture Partners, APERTURE Venture Partners, Jennison Associates, and Perceptive Advisors
Stock Issuance/Offering (2014): $104M backed by Undisclosed
Stock Issuance/Offering (2015): $86M with participation from Undisclosed
Stock Issuance/Offering (2016): $115M led by Undisclosed
Key Investors in Otonomy
Novo Ventures
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in life sciences.
Domain Associates
An investment advisory firm established in 1985, specializing in biotech investments with a track record of supporting numerous IPOs and M&A events.
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics with a multi-stage investment strategy.
What's next for Otonomy?
With the support of its recent capital infusion, Otonomy is well-positioned to advance its clinical programs and refine its commercialization strategy. The company's focus remains on navigating the regulatory landscape to bring its pipeline of neurotology therapeutics to market. Future strategic efforts will likely prioritize the expansion of its drug delivery platform, potentially exploring new therapeutic indications that leverage its existing technological infrastructure. As the company matures, the emphasis will shift toward scaling operational capabilities and fostering partnerships that enhance its market presence in the global healthcare ecosystem.
See full Otonomy company page
